Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001437749-25-001893
Filing Date
2025-01-27
Accepted
2025-01-27 12:08:54
Documents
15
Period of Report
2025-01-27
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A mbrx20250127_8ka.htm   iXBRL 8-K/A 27042
6 m01.jpg GRAPHIC 10270
  Complete submission text file 0001437749-25-001893.txt   190304

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20250127.xsd EX-101.SCH 3409
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20250127_def.xml EX-101.DEF 11792
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20250127_lab.xml EX-101.LAB 15821
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20250127_pre.xml EX-101.PRE 12007
17 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20250127_8ka_htm.xml XML 3020
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671997 | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-37758 | Film No.: 25556708
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)